Cargando…

Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial

BACKGROUND: Acute kidney injury (AKI) is frequent in patients resuscitated from cardiac arrest (CA) and may worsen outcome. Experimental data suggest a renoprotective effect by treating these patients with a high dose of erythropoietin (Epo) analogues. We aimed to evaluate the efficacy of epoetin al...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillemet, Lucie, Jamme, Matthieu, Bougouin, Wulfran, Geri, Guillaume, Deye, Nicolas, Vivien, Benoît, Varenne, Olivier, Pène, Frédéric, Mira, Jean-Paul, Barat, Florence, Treluyer, Jean-Marc, Hermine, Olivier, Carli, Pierre, Coste, Joël, Cariou, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367106/
https://www.ncbi.nlm.nih.gov/pubmed/32699621
http://dx.doi.org/10.1093/ckj/sfz068
_version_ 1783560356642160640
author Guillemet, Lucie
Jamme, Matthieu
Bougouin, Wulfran
Geri, Guillaume
Deye, Nicolas
Vivien, Benoît
Varenne, Olivier
Pène, Frédéric
Mira, Jean-Paul
Barat, Florence
Treluyer, Jean-Marc
Hermine, Olivier
Carli, Pierre
Coste, Joël
Cariou, Alain
author_facet Guillemet, Lucie
Jamme, Matthieu
Bougouin, Wulfran
Geri, Guillaume
Deye, Nicolas
Vivien, Benoît
Varenne, Olivier
Pène, Frédéric
Mira, Jean-Paul
Barat, Florence
Treluyer, Jean-Marc
Hermine, Olivier
Carli, Pierre
Coste, Joël
Cariou, Alain
author_sort Guillemet, Lucie
collection PubMed
description BACKGROUND: Acute kidney injury (AKI) is frequent in patients resuscitated from cardiac arrest (CA) and may worsen outcome. Experimental data suggest a renoprotective effect by treating these patients with a high dose of erythropoietin (Epo) analogues. We aimed to evaluate the efficacy of epoetin alpha treatment on renal outcome after CA. METHODS: We did a post hoc analysis of the Epo-ACR-02 trial, which randomized patients with a persistent coma after a witnessed out-of-hospital CA. Only patients admitted in one intensive care unit were analysed. In the intervention group, patients received five intravenous injections of Epo spaced 12 h apart during the first 48 h, started as soon as possible after resuscitation. In the control group, patients received standard care without Epo. The main endpoint was the proportion of patients with persistent AKI defined by Kidney Disease: Improving Global Outcomes criteria at Day 2. Secondary endpoints included the occurrence of AKI through Day 7, estimated glomerular filtration rate (eGFR) at Day 28, haematological indices and adverse events. RESULTS: A total of 162 patients were included in the primary analysis (74 in the Epo group, 88 in the control group). Baseline characteristics were similar in the two groups. At Day 2, 52.8% of the patients (38/72) in the intervention group had an AKI, as compared with 54.4% of the patients (46/83) in the control group (P = 0.74). There was no significant difference between the two groups regarding the proportion of patients with AKI through Day 7. Among patients with persistent AKI at Day 2, 33% (4/12) in the intervention group had an eGFR <75 mL/min/1.73 m(2) compared with 25% (3/12) in the control group at Day 28 (P = 0.99). We found no significant differences in haematological indices or adverse events. CONCLUSION: After CA, early administration of Epo did not confer any renal protective effect as compared with standard therapy.
format Online
Article
Text
id pubmed-7367106
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73671062020-07-21 Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial Guillemet, Lucie Jamme, Matthieu Bougouin, Wulfran Geri, Guillaume Deye, Nicolas Vivien, Benoît Varenne, Olivier Pène, Frédéric Mira, Jean-Paul Barat, Florence Treluyer, Jean-Marc Hermine, Olivier Carli, Pierre Coste, Joël Cariou, Alain Clin Kidney J Original Articles BACKGROUND: Acute kidney injury (AKI) is frequent in patients resuscitated from cardiac arrest (CA) and may worsen outcome. Experimental data suggest a renoprotective effect by treating these patients with a high dose of erythropoietin (Epo) analogues. We aimed to evaluate the efficacy of epoetin alpha treatment on renal outcome after CA. METHODS: We did a post hoc analysis of the Epo-ACR-02 trial, which randomized patients with a persistent coma after a witnessed out-of-hospital CA. Only patients admitted in one intensive care unit were analysed. In the intervention group, patients received five intravenous injections of Epo spaced 12 h apart during the first 48 h, started as soon as possible after resuscitation. In the control group, patients received standard care without Epo. The main endpoint was the proportion of patients with persistent AKI defined by Kidney Disease: Improving Global Outcomes criteria at Day 2. Secondary endpoints included the occurrence of AKI through Day 7, estimated glomerular filtration rate (eGFR) at Day 28, haematological indices and adverse events. RESULTS: A total of 162 patients were included in the primary analysis (74 in the Epo group, 88 in the control group). Baseline characteristics were similar in the two groups. At Day 2, 52.8% of the patients (38/72) in the intervention group had an AKI, as compared with 54.4% of the patients (46/83) in the control group (P = 0.74). There was no significant difference between the two groups regarding the proportion of patients with AKI through Day 7. Among patients with persistent AKI at Day 2, 33% (4/12) in the intervention group had an eGFR <75 mL/min/1.73 m(2) compared with 25% (3/12) in the control group at Day 28 (P = 0.99). We found no significant differences in haematological indices or adverse events. CONCLUSION: After CA, early administration of Epo did not confer any renal protective effect as compared with standard therapy. Oxford University Press 2019-06-17 /pmc/articles/PMC7367106/ /pubmed/32699621 http://dx.doi.org/10.1093/ckj/sfz068 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Guillemet, Lucie
Jamme, Matthieu
Bougouin, Wulfran
Geri, Guillaume
Deye, Nicolas
Vivien, Benoît
Varenne, Olivier
Pène, Frédéric
Mira, Jean-Paul
Barat, Florence
Treluyer, Jean-Marc
Hermine, Olivier
Carli, Pierre
Coste, Joël
Cariou, Alain
Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial
title Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial
title_full Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial
title_fullStr Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial
title_full_unstemmed Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial
title_short Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial
title_sort effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratory post hoc analyses from an open-label randomized trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367106/
https://www.ncbi.nlm.nih.gov/pubmed/32699621
http://dx.doi.org/10.1093/ckj/sfz068
work_keys_str_mv AT guillemetlucie effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT jammematthieu effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT bougouinwulfran effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT geriguillaume effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT deyenicolas effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT vivienbenoit effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT varenneolivier effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT penefrederic effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT mirajeanpaul effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT baratflorence effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT treluyerjeanmarc effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT hermineolivier effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT carlipierre effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT costejoel effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial
AT carioualain effectsofearlyhighdoseerythropoietinonacutekidneyinjuryfollowingcardiacarrestexploratoryposthocanalysesfromanopenlabelrandomizedtrial